Mustang Bio, Inc. MBIO · Stock Open Mustang Bio, Inc. in new tab
Mustang Bio, Inc. Analysis (MBIO)
Is Mustang Bio, Inc. a good investment? Mustang Bio, Inc. (MBIO) is currently trading at 0.5500 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.62. This relatively low multiple may signal that Mustang Bio, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Mustang Bio, Inc. is expected to release its next earnings report on Nov. 18, 2026. The market consensus estimate for Forward EPS is -0.35.
Investor FAQ
Does Mustang Bio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Mustang Bio, Inc.?
Mustang Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 18, 2026. The company currently has a trailing EPS of -0.42.
Company Profile
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| April 4, 2023 | 0.07 |
| Jan. 16, 2025 | 1:50 |
Community Discussion